Podcasts about Oncology

In this episode, a16z Bio + Health investment partner Becky Pferdehirt chats with Robbie Majzner, an Assistant Professor of Pediatrics in the Division of Hematology and Oncology at Stanford, and co-founder of Link Cell Therapies.Together, they discuss Robbie's recent paper published in Nature. The paper outlines a new approach to develop logic gated intracellular network, or LINK CAR T cells, as a means to simultaneously enhance both the safety and efficacy of these novel cell therapies.Additional reading:Co-opting signalling molecules enables logic-gated control of CAR T cells, Nature

Mike Putman, Todd C. Lee, John Mandrola and I debate the recent JAMA paper on RCT Duplicate. This is a spirited round table discussion on the limitations of observational data. If you are reading this, leave a comment as a review!

Dr Pavlos Msaouel: https://faculty.mdanderson.org/profiles/pavlos_msaouel.html 0:00 Pretext and context MD Anderson Cancer Center 1:42 The Early Experiences That Shaped Dr Msaouel 3:39 The System of Cancer Research In the United States 5:25 FDA Drug Approvals and Special Designations For Oncology 11:09 A trade-off in our current system 12:35 Whoops

Finding and seeing joy in life can be a challenge. When you have been diagnosed with cancer four times and lost numerous family members to the disease, it can be even more of a challenge. However, Sulie Spencer has found ways to be victorious in body, mind and spirit and shines her light on every path she crosses. She is a great example of what faith in God, prayer and early detection can do. As a 46-year survivor, she is here today on our podcast alongside her daughter, Julie Washington, to share their family's story, how to find joy in life despite life's ups and downs, and how Julie was able to capture her mother's spirit and passion for cooking in a book called Recipes for Joyous Living: A Story of Inspiration.

In this episode, we explore the pros and cons of integrating ChatGPT, an advanced AI technology, into our health care system. Our guest, Liudmila Schafer, a board-certified medical oncologist, guides us through the potential benefits, such as early diagnosis and improved medication adherence, as well as the potential downsides, such as incorrect predictions and increased anxiety for some patients. Join us as we discuss the role of AI in health care and its potential implications. Liudmila Schafer is a board-certified, award-winning medical oncologist, an associate professor of medicine, and author of The Other Side of Oncology. She is CEO, The Doctor Connect consultancy specializing in helping physicians to unlock their full potential for passion-driven business and media appearances utilizing credentials through "national impact strategy." She can be reached on Twitter @MdLiudmila, Instagram @dr_liudmilas, Facebook, and YouTube. She shares her story and discusses her KevinMD article, "The pros and cons of using ChatGPT for your health care needs." The Podcast by KevinMD is brought to you by the Nuance Dragon Ambient eXperience. Ambient intelligence augments human capabilities to make our lives easier. The applications are many, especially in health care. Ambient clinical intelligence is offsetting the most pressing challenges in health care today, such as burnout, physician shortages, physician and patient dissatisfaction, and underperforming financial outcomes, by applying the technology to clinical documentation.  The Nuance Dragon Ambient eXperience, or DAX for short, utilizes artificial intelligence and natural language processing to automatically document care. It securely listens to and captures the natural, clinician-patient encounter conversation unobtrusively, and turns that conversation into a clinical note for the clinician's review and signature directly in the electronic health record. You just talk naturally, and DAX does the rest.  DAX is being used by thousands of physicians across 30 different specialties nationwide. It has already won the Silver Stevie award in the health care technology category and was ranked #1 for improving clinician experience in KLAS's top 20 emerging solutions. VISIT SPONSOR → https://nuance.com/daxinaction SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended GET CME FOR THIS EPISODE → https://earnc.me/D2UIXg Powered by CMEfy.

Join Nico Salgado on the Small Axe Podcast as he sits down with real estate investor Savannah Arroyo to discuss her journey in the industry. Starting as a nurse, Savannah transitioned to real estate to provide resources for healthcare professionals. She shares her experiences in single-family homes and multifamily syndications, emphasizing the importance of education and networking. Savannah's investment markets include Atlanta and Oregon, and she reveals her strategies for raising capital through social media and referrals. Tune in to learn about her partnership with her husband, their investment approach, and the key factors that contribute to their success.  Here's a breakdown of what to expect in this episode: From Nurse to Real Estate: Savannah's Journey  Education and Networking: The Keys to Success  Raising Capital and Building Trust: Strategies for Success  Partnership Dynamics and Investment Strategy  Navigating the Real Estate Market: Lessons and Insights  And so much more! About Savannah Arroyo: Savannah started her nursing career in 2014 – working in a variety of clinical settings including: Oncology, Med/Surg/Tele, PreOp/PACU, Ortho, Cath Lab, Specials, GI Lab, Non-Invasive Cardiology.  After receiving her master's degree in Nursing Leadership and Administration – Savannah spent much of her nursing career climbing the corporate ladder within the healthcare system, operating large departments and medical practices. Check Savannah Arroyo on... Website: https://networthnurse.co/ Website: https://investhealth.com/ LinkedIn: https://www.linkedin.com/in/savannah-arroyo/ Instagram: https://www.instagram.com/thenetworthnurse/?hl=en Facebook: https://www.facebook.com/profile.php?id=100063703982493 Twitter: https://twitter.com/networthnurse Connect with Nico Salgado! Website: www.smallaxecommunities.com Facebook: https://www.facebook.com/nicosalgado456, Podcast: https://podcasts.apple.com/us/podcast/small-axe-podcast/id1528971543 LinkedIn: https://www.linkedin.com/in/nicosalgado456/ Spotify: https://open.spotify.com/show/6edqbvXc6JCXuSg2lbSJeD YouTube: https://www.youtube.com/@nicosalgado1753 Amazon: https://www.amazon.com/-/es/dp/B08K4T9YTH

Early treatment of myeloma, dual vs. single maintenance, and finally transplant or no transplant.

Why the USPSTF is wrong

It is hard to talk to a loved one about their serious illness. And it can be hard to counsel families about how to communicate well.Knowing your own communication style and that of the patient can help make communication easier.This podcast will discuss 6 different communication styles: Direct & open, reserved & private, emotional & expressive, passive or reliant, information-seeking and avoidant or denying. Trying to match communication styles helps connection.Which communication style do you use?I'm glad you're here,Dr CDelia Chiaramonte, MDI have a few spots available for coaching families who are facing complex or serious illness. Reach out at hello@integrativepalliative.com if you'd like to learn more about how serious illness coaching works. There are also free resources available at www.integrativepalliative.com. You don't have to do this alone. Managing uncertainty and overwhelm is the key to navigating the experience of loving someone who is ill, and this is available through IPI's Conscious Coping program.You'll get practical tools to support your loved one and yourself, important insights, skills to talk about tough topics and a supportive community, so you don't need to do this alone. 1:1 coaching is also available.Click Here to Stay in Touch:https://trainings.integrativepalliative.com/IPI-stay-in-touchHere's a Free Guide for You if Your Loved One Is Ill:The 10 Best Ways to Help When Your Loved One Has A Serious Illnesshttps://trainings.integrativepalliative.com/pl/2147661904 And Here's a Free Guide for Clinicians:How to Add Integrative Medicine To Your Practicehttps://trainings.integrativepalliative.com/pl/2147657852Please review this podcast wherever you listen and forward your favorite episode to a friend! Thanks for helping me spread the word about heart-centered care for people with complex and serious illness.

This week on "Pushing the Limit” Dr. Daniel Weber is internationally renowned as an informative and passionate speaker, traveling extensively lecturing on modern botanical medicine, psycho physical diseases, microbiome and its spectrum of diseases as well as cancer. Dr Weber has nearly 50 years experience across a wide variety of fields including  Chinese Medicine Integrated Oncology Herbal Medicine CEO of Panaxea™ International, Autoimmune diseases Botanical oncology isolates Dr Weber is a deep thinker, a master, philosopher, pioneer, artist and this discussion dives deep into medical philosophies, history, oriental medicine and western medicine, paradigm shifts that humanity is experiencing and much more.   You will come away inspired and challenged by this interview and if you are someone dealing with cancer then Dr Weber is someone you want to have on your radar and learn from.   If you want to learn more about Dr Weber's work go to  https://drdanielweber.com/   Or to visit his botanicals company Panaxea go to https://au.panaxea.com/   If you want help with your cancer please also check out Lisa's Ebook "What your oncologist isn't telling you"    Dr Daniel Webber Bio Daniel is author of many books and published articles on integrative medicine. Daniel is deeply committed to research and evidence based medicine (EBM), and works to promote integrative clinics. Daniel is Vice-Chair Oncology of the World Federation of Chinese Medicine Societies and editor of the Journal of Chinese Integrative Medicine. Daniel is a member of the Mederi Scientific Advisory Board, USA, and Advisor to the NIH and Global Consortium of Oncology and Chinese Medicine (Beijing). Daniel holds a Master Degree in Botanical Medicine and has been a Registered Somatic Psychotherapist since 1987. Daniel Weber is a Doctor of Health Science (DSc) from Charles Sturt University and maintains an international practice from his Clinic.   Health Optimisation and Life Coaching with Lisa Tamati Lisa offers solution focused coaching sessions to help you find the right answers to your challenges. Topics Lisa can help with:  Lisa is a Genetics Practitioner, Health Optimisation Coach, High Performance and Mindset Coach. She is a qualified Ph360 Epigenetics coach and a clincian with The DNA Company and has done years of research into brain rehabilitation, neurodegenerative diseases and biohacking. She has extensive knowledge on such therapies as hyperbaric oxygen,  intravenous vitamin C, sports performance, functional genomics, Thyroid, Hormones, Cancer and much more. Testing Options Comprehensive Thyroid testing DUTCH Hormone testing Adrenal Testing Organic Acid Testing Microbiome Testing Cell Blueprint Testing Epigenetics Testing DNA testing Basic Blood Test analysis She can help you navigate the confusing world of health and medicine and can advocate for you. She can also advise on the latest research and where to get help if mainstream medicine hasn't got the answers you are searching for whether you are facing challenges from cancer to gut issues, from depression and anxiety, weight loss issues, from head injuries to burn out.: Consult with Lisa    Join our Patron program and support the show Pushing the Limits' has been free to air for over 8 years. Providing leading edge information to anyone who needs it. But we need help on our mission.  Please join our patron community and get exclusive member benefits (more to roll out later this year) and support this educational platform for the price of a coffee or two You can join by going to  Lisa's Patron Community Lisa's Anti-Aging and Longevity Supplements  Lisa has spent years curating a very specialised range of exclusive longevity, health optimising supplements from leading scientists, researchers and companies all around the world.  This is an unprecedented collection. The stuff Lisa wanted for her mum but couldn't get in NZ. Check out the range at her LongLifeLabs shop   Subscribe to our popular Youtube channel  with over 600 videos, millions of views, a number of full length documentaries, and much more. You don't want to miss out on all the great content on our Lisa's youtube channel. Youtube   Order Lisa's Books My latest book Relentless chronicles the inspiring journey of how my mother and I defied the odds after an aneurysm left my mum, Isobel, with massive brain damage at age 74. The medical professionals told me there was absolutely no hope of any quality of life again. Still, I used every mindset tool, years of research and incredible tenacity to prove them wrong and bring my mother back to full health within three years. Get your copy here: Lisa's Books   Our NMN Bio Flagship Longevity Range A range by molecular biologist Dr Elena Seranova NMN: Nicotinamide Mononucleotide, an NAD+ precursor Researchers have found that Nicotinamide Adenine Dinucleotide or NAD+, a master regulator of metabolism and a molecule essential for the functionality of all human cells, decreases dramatically over time.   What is NMN? NMN Bio offers a cutting edge Vitamin B3 derivative named NMN (beta Nicotinamide Mononucleotide) that can boost the levels of NAD+ in muscle tissue and liver. Take charge of your energy levels, focus, metabolism and overall health so you can live a happy, fulfilling life. Founded by scientists, NMN Bio offers supplements of the highest purity and rigorously tested by an independent, third-party lab. Start your cellular rejuvenation journey today.   Support Your Healthy Aging We offer powerful third-party tested NAD+ boosting supplements so you can start your healthy ageing journey today. Shop now: NMNBIO NMN (beta Nicotinamide Mononucleotide) 250mg | 30 capsules NMN (beta Nicotinamide Mononucleotide) 500mg | 30 capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 250mg | 30 Capsules 6 Bottles | NMN (beta Nicotinamide Mononucleotide) 500mg | 30 Capsules Boost Your NAD+ Levels — Healthy Ageing: Redefined Cellular Health Energy & Focus Bone Density Skin Elasticity DNA Repair Cardiovascular Health Brain Health Metabolic Health Listen to the episodes with Dr Seranova on the show: https://www.lisatamati.com/podcast--dr-elena-seranova/ https://www.lisatamati.com/podcast--dr-elena-seranova-part-3/   Perfect Amino Supplement by Dr David Minkoff Introducing PerfectAmino PerfectAmino is an amino acid supplement that is 99% utilized by the body to make protein. PerfectAmino is 3-6x the protein of other sources with almost no calories. 100% vegan and non-GMO. The coated PerfectAmino tablets are a slightly different shape and have a natural, non-GMO, certified organic vegan coating on them so they will glide down your throat easily. Fully absorbed within 20-30 minutes! No other form of protein comes close to PerfectAminos Listen to the episode with Dr MInkoff here:  Ketone Products by HVMN The world's best  exogenous Ketone IQ Listen to the episode with Dr Latt Mansor Lisa's  ‘Fierce' Sports Jewellery Collection For Lisa's gorgeous and inspiring sports jewellery collection, 'Fierce', go to Jewellery   For Vielight Device Vielight brain photobiomodulation devices combine electrical engineering and neuroscience. To find out more about photobiomodulation, current studies underway and already completed and for the devices mentioned in this video go to www.vielight.com Use code "tamati" at checkout to get a 10% discount on any of their devices.   Enjoyed This Podcast? If you did, subscribe and share it with your friends! If you enjoyed tuning in, then leave us a review and share this with your family and friends. Have any questions? You can contact my team through email (support@lisatamati.com) or find me on Facebook, Twitter, Instagram and YouTube. For more episode updates, visit my website. You may also tune in on Apple Podcasts. To pushing the limits, Lisa and team

In this episode of the FreshRN Podcast, Kati interviews Morgan Melancon MSN, RN, CCRN-K and Annabeth Davis, MSN, RN, NPD-BC. It's Part II of our two-part interview. Morgan is the director of Nursing Education and Professional Development at St. Jude Children's Research Hospital in Memphis, and Annabeth is the manager of Transition to Practice within the department of Nursing Education of the same organization. We discuss: Special training required to give chemotherapy What people love about working oncology and what's particularly challenging End of life care Specific common nursing responsibilities unique to oncology Show notes are located here: https://www.freshrn.com/st-judes-oncology/ If you're interested in learning more about St. Jude's nurse residency program, click here: https://www.stjude.org/jobs/hospital/clinical-careers/nursing/new-nurse-graduates.html Get weekly tips, encouragement, stories from the bedside and more - just for nursing students and new nurses at: https://www.freshrn.com/ Connect With Me Online! Facebook: https://www.facebook.com/FreshRN Twitter: https://twitter.com/Kati_Kleber Pinterest: https://www.pinterest.com/Fresh_RN/ Instagram: https://www.instagram.com/kati_kleber/ TikTok: https://www.tiktok.com/@freshrn 

In this episode of the Susan G. Komen "Real Talk" podcast series, Alison LoCoco and Kate Ratajczak share their personal journeys of being diagnosed with breast cancer while pregnant. As guests on the show, they candidly discuss the challenges they faced during this difficult time and offer insight into how they navigated the complex and emotional decisions that came with their diagnoses. Hear firsthand how these two women balanced pregnancy and breast cancer treatment, while also taking care of themselves and their families. With this episode, the series aims to provide a platform for honest and raw conversations about breast cancer, with a focus on underrepresented experiences such as pregnancy and motherhood. Tune in to gain valuable insight and a new perspective on breast cancer, from two brave women who have been there.

The Use of Robotics/Minimally Invasive Surgery for Urologic Cancers with guest Dr. Joseph Brito May 7, 2023 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Tammy Triglianos, DNP, ANP-BC, AOCNP!

Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Susan Rux, PhD!

Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Nick Escobedo, DNP, RN!

Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Abbey Kaler, APRN, FNP-C!

Listen to this live podcast from the 2023 Oncology Nursing Society (ONS) Congress with Doyle Bosque, RN, CNML!

Featuring perspectives from Drs Andrew J Armstrong and Rana R McKay, including the following topics: Introduction (0:00) Intensification of endocrine therapy: Emerging role in nonmetastatic disease; choice of androgen deprivation therapy (3:31) Management of castration-resistant M0 disease; PROTACs, CDK4/6 inhibitors and other new endocrine approaches (16:18) Hormone-sensitive metastatic disease — Choice of antiandrogen (26:48) Castration-resistant metastatic disease (37:06) Genomic evaluation; PARP inhibitors for metastatic disease (46:24) Ideal sequencing of PARP inhibitors; management of associated side effects (55:21) Biomarker testing; MSI-high disease; TKIs with immunotherapy; bispecific antibodies? (59:42) CME information and select publications

In this week's episode we'll review imbalances in gut microbiota may impact the efficacy and safety of immunochemotherapy in patients with diffuse large B-cell lymphoma. Next, the NFIA-ETO2 fusion, found exclusively in pediatric patients with pure erythroid leukemia, impairs the normal process of erythroid differentiation. Finally, we'll look at the effectiveness of nirmatrelvir plus ritonavir in patients with CLL infected with SARS-CoV-2 during the Omicron surge.  

Dr. Shani Fox has stepped up over and over again to help cancer survivors through their greatest challenges, including taming the fear of recurrence, repairing devastated relationships, and making the most of the life they survived for. Bringing her unique expertise as both a holistic physician and certified life mastery coach, she has impacted countless cancer survivors with her life-changing workshops and warm personal presence.  Dr. Shani is the author of The Cancer Survivor's Fear First Aid Kit and is a popular speaker and podcast guest for survivor communities. Her posts and articles have been published in the Huffington Post, Breast Cancer Wellness magazine, and the peer-reviewed Natural Medicine Journal. ✨A few highlights from the show:   1. Listen to your inner voice and get good at listening to what you know is true. 2. People often do not feel heard in the medical system. 3. Fear of recurrence is the most common side effect of cancer. 4. Many people finish treatment feeling disempowered because the system has been making decisions for them. 5. Cancer is complex! You can't simply draw a straight line from a certain cause to the reason why a person got cancer.

As we see an increasing number of culturally diverse patients in our US-based practices or on the mission field, our understanding of cultural influences in healthcare and our own biases is essential. How can we develop an eye to see where a patient’s values and worldview may differ from our own? We will review an approach to cultural humility highlighted by medical missions case studies. Presentation Slides: https://bit.ly/gmhc2022_davidnarita_culturalhumility

Beth Hoag. The Woman and Physio Radically changing Oncology Management "It's not about just being blessed…I dug in deep and earned this! You are so much more than your cancer" Beth Hoag Beth is Helping cancer survivors reclaim their power to live with connection, comfort & confidence because  #qualityoflifematters

While proton therapy is still uncommon in the US, it's quickly gaining traction as a more precise cancer treatment with a lot fewer side effects for our patients.  But is it worth knowing about if you don't have a proton therapy center in your area?Short answer: ABSOLUTELY!Dive into the world of proton therapy with me as I interview Dr. Andrew Lee of Texas Center for Proton Therapy.  We covered everything you need to know about proton therapy, including how proton therapy compares to more conventional XRT, side effects of proton therapy, & just what the research shows us about proton therapy's benefits.Listen now!Download your FREE Quick Guide to Treating Patients with Cancer.Because it's not if, it's when you'll treat a person with cancer.Follow TheOncoPT on Instagram:https://Instagram.com/TheOncoPT This episode is brought to you by our brand new Cancer Basics Course. With the Cancer Basics Course, you'll get our exact blueprint to start treating people with cancer confidently & competently. No more ramshackling together your oncology knowledge.Start treating your patients with cancer confidently & competently TODAY. Register now at TheOncoPT.com/cancerbasicscourseFollow TheOncoPT on Instagram.Follow TheOncoPT on TikTok.Follow TheOncoPT on Twitter.

As a nurse, have you been bullied or do you ever wonder if others might perceive you as a bully?  Join Caroline, Laura, Neil and Maritess as they share their personal stories, perspectives and strategies for how to deal with nurse bullying. Also, find out which co-host admits to having once been a bully and hear about her personal transformation.     CO-HOSTS Caroline Ashman, MSN, RN, CMSRN was born and raised in England. She had two dreams in life – to become a nurse and live in the United States. She accomplished the first task in 1985 and then in 1991, immigrated to America. She currently serves as a Nurse Leader. She has also been afforded the wonderful opportunity to teach Med Surg Review Courses across the United States and in Europe for AMSN. Collecting air miles and sharing stores along the way, she is thrilled to join the Podcast team and recognize that the specialty of medical surgical nursing is alive and well. Caroline lives with her husband Jimmy, in metro Atlanta and has two grown daughters, Jennifer & Emily.   Laura Johnson, MSN, RN, CMSRN has been a nurse since 2008 with a background in Med/Surg and Oncology.  She has held many positions throughout my career including management and leadership.  Laura obtained her MSN in nursing education in 2018.  Since then, she has worked as a bedside educator with both experienced staff and nurse residency with specialties in end of life and mentorship.  She is currently working as an NPD practitioner for oncology and bone marrow transplant units.    Neil H. Johnson, RN, BSN, CMSRN, is a native New Yorker that has settled in North Carolina for the last 24 years. He has worked his way up the Nursing ladder from a C.N.A to achieving his BSN, and is in pursuit of his MSN in Nurse Education. He has worked in Oncology, Palliative, Behavioral Health, but his heart always brings him back to Medical-Surgical Nursing, where he holds his certification.He is currently a FLEX pool Med/Surg night nurse for Moses Cone Hospital System, floating to 4 facilities.    Maritess M. Quinto, DNP, RN, NPD-BC, CMSRN is a Clinical Educator currently leading a team of educators who is passionately helping healthcare colleagues, especially newly graduate nurses. She was born and raised in the Philippines and immigrated to the United States with her family in Florida. Her family of seven (three girls and two boys with her husband who is also a Registered Nurse) loves to travel, especially to Disney World. She loves to share her experiences about parenting, travelling, and, of course, nursing!

The early 1970's saw the start of the medical specialty we now know as oncology. How does one create standards and practices for patient care during that time? Dr. John Glick is a pioneer during the dawn of oncology. He says that early work involved humanity, optimism, and compassion, all of which were the foundation of his career. Dr Glick describes the clinical experiences that drove him to oncology (4:28), his rapport with patients, which was portrayed in Stewart Alsop's book Stay of Execution (9:21), and his groundbreaking work developing the medical oncology program at the University of Pennsylvania (12:22). Speaker Disclosures Dr. David Johnson: Consulting or Advisory Role – Merck, Pfizer, Aileron Therapeutics, Boston University Dr. Patrick Loehrer: Research Funding – Novartis, Lilly Foundation, Taiho Pharmaceutical Dr. John Glick: None More Podcasts with Oncology Leaders    Oncology, Etc. – In Conversation with Dr. Richard Pazdur (Part 1) Oncology, Etc. – HPV Vaccine Pioneer Dr. Douglas Lowy (Part 1) Oncology, Etc. – Rediscovering the Joy in Medicine with Dr. Deborah Schrag (Part 1)  If you liked this episode, please follow the show. To explore other educational content, including courses, visit education.asco.org. Contact us at education@asco.org.   TRANSCRIPT Disclosures for this podcast are listed in the podcast page. Pat Loehrer: Welcome to Oncology, Etc. This is an ASCO education podcast. I'm Pat Loehrer, Director of Global Oncology and Health Equity at Indiana University. Dave Johnson: And I'm Dave Johnson, a medical oncologist at the University of Texas Southwestern in Dallas, Texas. If you're a regular listener to our podcast, welcome back. If you're new to Oncology, Etc., the purpose of our podcast is to introduce listeners to interesting people and topics in and outside the world of oncology. Today's guest is someone well-known to the oncology community. Dr. John Glick is undoubtedly one of oncology's most highly respected clinicians, researchers, and mentors. I've always viewed John as the quintessential role model. I will add that for me, he proved to be a role model even before I met him, which hopefully we'll talk about a little bit later.   To attempt to summarize John's career in a paragraph or two is really impossible. Suffice it to say, he is to the University of Pennsylvania Cancer Center what water is to Niagara Falls. You can't have one without the other. After completing his fellowship at NCI in Stanford, John joined the Penn faculty in 1974 as the Ann B. Young Assistant Professor. Some five decades later, he retired as the director of one of the most highly respected comprehensive cancer centers in the nation. Among his many notable accomplishments, I will comment on just a few. He established the Medical Oncology program at Penn and subsequently directed the Abramson Cancer Center from 1985 to 2006. Interestingly, he established the Penn Medicine Academy of Master Clinicians to promote clinical excellence in all subspecialties across the health system. He's been a driving force in philanthropy at Penn Medicine, culminating in his role as Vice President Associate Dean for Resource Development.  Over the past several decades, he has helped raise over half a billion dollars for Penn Med. We need you on our team, John. As a clinician scholar, John's research has helped shape standards of care for both breast cancer and lymphomas. For example, he pioneered the integration of adjuvant chemotherapy and definitive breast irradiation for early-stage breast cancer. In 1985, he chaired the pivotal NCI Consensus Conference on adjuvant chemotherapy for breast cancer. He also was a driving force in a clinical landmark study published in The New England Journal some 20 or so years ago about the role of bone marrow transplant for advanced breast cancer. Most impressive of all, in my opinion, is John's legacy as a mentor to multiple generations of medical students, residents, and fellows.   So, John, we want to thank you for joining us and welcome. Thought we might start by having you tell us a little about your early life, your family, your parents, where you grew up, and how you got into medicine. Dr. John Glick: Well, thank you for having me on the podcast, Pat and David, it's always a pleasure to be with you and with ASCO. I grew up in New York City in Manhattan. My father was a well-known dermatologist. He was my role model. And from the age of eight, I knew I wanted to be a doctor. Nothing else ever crossed my mind. But having seen my father's many interests outside of medicine, I realized from very early that there was much more to medicine than just science. And that really induced me, when I went to college, to major in the humanities, in history, art history, and I actually took the minimum number of science courses to get into medical school. That probably wouldn't work today, but it was the start of my interest in humanism, humanities, and dealing with people outside of the quantitative sciences.  Dave Johnson: So that's reflected in how we all view you, John. You're one of the most humanistic physicians that I know personally. I wonder if you could tell us about your interest in medical oncology, and in particular, as one of the pioneers in the field. I mean, there wasn't really even a specialty of medical oncology until the early 1970s. So, how in the world did you get interested in oncology and what drew you to that specialty? Dr. John Glick: Well, I had two clinical experiences that drove me into oncology. The first, when I was a third year medical student at Columbia PNS, my first clinical rotation in internal medicine, I was assigned a 20-year-old who had acute leukemia, except he was not told his diagnosis. He was told he had aplastic anemia, receiving blood and platelets, and some form of chemotherapy. And I spent a lot of time just talking to him as an individual, not just taking care of him. And we became friends. And he was then discharged, only to be readmitted about two weeks later. And in the elevator, the medical assistant had his admission sheet, and unfortunately, it was facing the patient, and it had his diagnosis, acute leukemia. So he came into the ward and he confronted me. "Why didn't you tell me I had acute leukemia?" Well, I couldn't say the attendees forbade me to do that. So I took what today we would call ‘the hit', and apologized. But it stimulated me to reflect that honesty with patients was extremely important, and that oncology was just in its infancy. We knew nothing about it. It was not considered even a specialty. I don't think we used the word "oncology."  But that inspired me to take an elective in my fourth year at PNS, at an indigent cancer hospital called the Francis Delafield Hospital. It only took care of indigent cancer patients, and there were wards, twelve patients in a ward, six on each side, and nobody would go see the patients. It was almost as if they were afraid that if they were to touch the patient, they would get cancer. And I started talking to the patients, and they were human beings, but nobody had told them their diagnosis. Nobody had told them if they were terminal. And there were a few patients who were getting a new drug at that time for multiple myeloma called melphalan, and they actually had relief of some of the symptoms, of their bone pain. But I realized that there was a huge void in medicine that I could possibly help to fill.  And that was the era of Vietnam, and so I applied to the National Cancer Institute to become a commissioned officer in the Public Health Service to avoid the draft, to be on a service with, at that time, some very notable oncologists Vince DeVita, Ed Henderson, Paul Carbone. I had read some of their papers, and I was lucky to be accepted. And I was a clinical associate at the National Cancer Institute. And that was life-changing because there every patient was considered to be potentially curable. The advances at that time using MOPP for Hodgkin's disease, C-MOPP for lymphoma, some treatments for leukemia. George Canellos pioneered the use of CMF for metastatic breast cancer. It was an amazing, amazing experience. That was in 1971 to ‘73. Oncology did not become a true specialty till ‘73, but my two years at NCI were formative.  However, I realized that there was something missing in my training. Everybody was considered curable, but I had never seen a patient with metastatic colon cancer, metastatic lung cancer. The radiotherapists there did not like to teach clinical associates, and I knew that there was a place called Stanford. And Stanford had Saul Rosenberg in medical oncology for lymphomas and Henry Kaplan in radiotherapy. So, everybody was going to California, and my wife and I packed up and went to California and spent a year at Stanford, which, combined with my training at the NCI, led me to the principles that guided my career in oncology; humanity, optimism, reality, compassion, and a love for clinical trials.  I was very, very fortunate to be there at the dawn of medical oncology shortly after I decided to go to Penn, which at that time did not have a medical oncologist. In fact, I was the only medical oncologist at Penn for four years and did every consult in the hospital for four years, much to the chagrin of my wife. But I was fortunate to have great mentors in my career: Paul Carbone, Vince DeVita, Saul Rosenberg, Henry Kaplan, among many, many others. And that impressed me about the importance of mentorship because my career would never have been where it was or is without these mentors. Pat Loehrer: John, just to echo what Dave said, you've been such a tremendous mentor for us. Dave and I particularly, you took us under your wings when you didn't know who we were. We were people in the Midwest. We weren't from any place shiny, but we really appreciate that. Dave Johnson: So, John, I mentioned at the very beginning that I met you before I met you, and the way I met you was through Stewart Alsop's book, Stay of Execution. He portrayed you as an extraordinarily caring individual, and it tremendously impacted me. It was one of the reasons why I chose oncology as a specialty. I realize it's been 50 or more years ago and most of our listeners will have no idea who Stewart Alsop was. And I wonder if you might share with us a little bit of that experience interacting with someone who was particularly well-known in that time as a columnist for The New York Times.  Dr. John Glick: His brother Joe Alsop and Stu Alsop were two of the most famous columnists at that time. Joe Alsop was a hawk right-winger who lived in the Vietnam War. Stewart was charming, was a centrist Democrat, wrote the back page for Newsweek for years. He and I had very similar educational backgrounds and interests. And we functioned on two different levels—one as a physician-patient, and then we became friends. And he and his wife adopted us into the Georgetown set.  And I received a lot of criticism for socializing with a patient. But over the years, I've been able to become friends with many of my patients, and I've been able to compartmentalize their medical care from our friendship. And I use the analogy if I was a doctor in a small town and I was the only doctor,  I'd be friends with people in town, with the pastor and likely the mayor. But I have always believed that patients can become your friends if they want it and if they initiated it.   Taking care of Stewart Alsop was an amazing, amazing experience. We didn't know what he had. People initially thought he had acute leukemia. In reality, he had myelodysplastic syndrome, but that hadn't been described yet. He had a spontaneous remission, which I rarely see, probably due to interferon released from a febrile episode, all his blasts went away in his marrow. One of my children's middle name is Stewart. But professionally and personally, it was an incredible experience. It taught me the importance of being available to patients. They had my home phone number. We didn't have cell phone numbers in those days. We had beepers, but they didn't work. And from that point on, I gave my home phone number to patients, and I actually trained my children how to answer the phone. “This is Katie Glick. How can I help you? My father's not home. You need my father? Can I have your phone number? I'll find him and he'll call you back.” Patients still remember my children and their way of answering the phone. Pat Loehrer: One of the things you did do is create this medical oncology program at Penn, which has graduated some incredible fellows that have become outstanding leaders in our field. But can you reflect a little bit about the process of creating something that was never created before, like a medical oncology program? Dr. John Glick: Well, I came to Penn, my first day. Person who recruited me was on sabbatical. I asked where my office was and there was no office. There was an exam room. There was a clinic for indigent patients which we scrubbed by hand. There was another office for patients who paid. Within two months, I had abolished that. We had one– I hate to use the word clinic, people still use the word clinic today, but one office that took care of all patients, irregardless of means.   I saw every oncology consult in the hospital for four years. But I had a mentor, not only Buz Cooper, but fortunately, Jonathan Rhoads was Chairman of Surgery, and he was also Chairman of the President's Cancer panel. And what he said at Penn in surgery became the law. And then when we introduced lumpectomy for breast cancer and radiotherapy, he endorsed it immediately. All the other surgeons followed suit. I don't think there's any hospital in the country that adopted lumpectomy and radiotherapy for breast cancer as quickly. And the surgeons were instrumental in my career.  Now, I was taking care of gliomas, head and neck cancers, and it was difficult. If I had a colorectal patient, I'd call Charles Moertel at Mayo Clinic and say, “What do I do?” I was there when Larry Einhorn in 1975 presented his data on testicular cancer with the platinum. Unbelievably inspiring, transformational. It also showed the importance of single-arm studies. You didn't have to do randomized studies because the results were so outstanding. And so in my career, I did both single-arm studies, proof of principle studies, and then many randomized trials through the cooperative groups.  But the first four years were very difficult. I didn't know what the word ‘work-life balance' meant in those days. If somebody was sick, I stayed and saw them. It was difficult introducing new principles. When I first mentioned platinum after Larry's presentation, I was laughed out of the room because this was a heavy metal. When patients were dying, they died in the hospital, and I wanted to hang up morphine to assist them. The nurses reported me to the administration. I had to fight to get the vending machines for cigarettes out of the hospital. So there were a lot of victories along the way and a lot of setbacks.  It took me several years to have an oncology unit of six beds, and now I think we have 150 or 160 beds and need more. So it was an interesting and, in retrospective, a wonderful experience, but I didn't know any better. Fortunately, I had a great wife who was working at Penn and then at Medical College of Pennsylvania, and she was incredibly understanding, never complained. And I think my kids knew that on Tuesdays and Thursdays, don't bring up anything difficult with dad because he's had a really tough day in clinic. Dave Johnson: We were not in that era, but we were very close. And many of the struggles that you had were beginning to dissipate by the time we were completing our training. But it was still a challenge. I mean, all those things. I gave my own chemotherapy for the first few years I was in practice. I don't know that our colleagues today who have trained in the last, say, 10 or 15 years, actually realize that that was what we did. Most of the chemo was given in the hospital. It was not uncommon in the early days to have 20, 30, 40 inpatients that you would round on because there just wasn't an outpatient facility. But the corporate mind made a big difference, allowing us to give drugs like platinum in the outpatient arena. You span all of that era, and so you've seen the whole panoply of change that has taken place.  John, the other thing you did that has impressed me, in part because of my time as a Chair of Medicine, is you created this Academy of Master Clinicians. Can you tell us a bit about that and what was the motivation behind that?  Dr. John Glick: Ben had a strategic plan, and one of the pillars was talking about valuing clinical medicine and clinical excellence. But there was no implementation plan. It was sort of just words and left in the air. And I was no longer director of the cancer center, and I realized we had a lot of awards for research, awards for education, and no awards for clinical excellence. So I created the idea of having an academy and master clinician spend six months talking to all constituencies, chairs of various departments, directors of centers to get a buy-in. Wrote a three-page white paper for the dean, who approved it immediately. And then, as typical at Penn, I raised all the money for it. I went to one of my patients who was an executive at Blue Cross. I said I need $500,000 to start this program. And then subsequently, I raised $4 million to endow it. Today, it is the highest honor that a Penn clinician can receive.  You could be on any one of our multiple tracks. You have to see patients at least 60% of the time. You not only have to be a great doctor, you have to be a humanist. So the world's best thoracic surgeon who has a demeanor in the operating room that is not conducive to working with a nurse as a team doesn't get in. We emphasize professionalism, mentorship, citizenship, teaching, national reputation, local reputation, and clinical excellence. And so we've elected over 100 people, maybe 3% of the Penn faculty. We give an honorarium. We have monthly meetings now by Zoom. We have monthly meetings on various topics. We never have a problem getting any dean or CEO to come talk to us.  We were the first to do Penn's professionalism statement. The school subsequently adopted, and it's become the highest honor for a Penn clinician. It's very competitive. It's peer-reviewed. The dean has no influence. And we're very proud that 40% of the members of the academy are women. We have a high percentage of diversity compared to the numbers on our faculty, but you really have to be elected on merit, and some people that you might expected to be members of the academy aren't. It's one of the things I'm proudest of. It will go on in perpetuity because of the money we've raised. I think many of my accomplishments as a researcher will fade, as they typically do, but I'm very proud of the Academy, and I'm very proud of the people that I've mentored. Dave Johnson: It speaks to your values, John, and I think it's one of the reasons why you're so widely admired. Thank you for creating that. It proved to be a model for other institutions. I know that for a fact. One would think that valuing clinical care would be preeminent in medical schools, but in fact, it's often ignored. So again, I know that your colleagues at Penn appreciate your efforts in that regard.  Tell us a little about your term as ASCO president. What are you most proud about and what were your most difficult challenges? Dr. John Glick: Well, the most difficult challenge was that ASCO was in transition. I had to fire the company that ran the meeting. We had to decide that ASCO was going to hire a CEO. We hired John Durant, made a small headquarters, tiny staff, and did a lot of the work as being chief operating officer myself. It was the year that email was just getting started, and ASCO wasn't using it. So every Saturday from 8:00 to 6:00, I came into the office and my secretary wrote letters inviting people to be on the program committee or various committees. But it was a society in transition. The growth of membership was huge. The meeting sites had to be changed. We emphasized science. Some of the things that we did are still in existence today.  We formed the ASCO ACR Clinical Research Methods course. It's still given. That's one of our real highlights. We forged relationships with other societies, the National Coalition for Survivorship. We made the ASCO guidelines much more prominent. And I remember that we were going to publish the first guidelines on genetic testing for breast cancer, and the MCI went up in absolute arms, so I arranged a meeting. I was at the head of the table. On my right were Francis Collins, Richard Klausner, Bob Wittes, and a few other people. Then the ASCO people who wrote the guideline were on the left, and they didn't want us to publish it. They thought it was premature to have a guideline about genetic testing. And what I learned from that meeting is that you can agree to disagree with even the most prominent people in oncology and still maintain those relationships. But we did what's right, and we published a guideline on the JCO. There were so many wonderful things that happened at ASCO that I can hardly restate all that happened I guess 27 years later. It was exciting. ASCO was still young. There was a lot we had to do, and we could do it. You could just go ahead and do it. It was exciting. It was gratifying. It was one of the most fun years of my life. Dave Johnson: I mean, that transition from an outside company in many respects, controlling the premier activity of ASCO, its annual meeting to ASCO, taking that on, that defined ASCO, and that's what I remember most about your time as president. It was a bold move, and the hiring of John Durant was brilliant. I mean, he was such an incredible individual, and it was great that you guys were able to pull that off. Pat Loehrer: Thank you for what you've done.  You've had a number of your mentees if you will, and colleagues that have gone on to prominent positions, including, I think, at least three directors of NCI Cancer Centers. Can you just talk briefly how you would describe your mentoring style because you've been so successful? Dr. John Glick: First, there are two aspects. One is when people come to you, and then when you go to people, you sense they're in need. The key aspect of mentoring is listening. Not talking, listening. Looking for the hidden meanings behind what they're saying, not telling them what to do, presenting options, perhaps giving them clues on how to weigh those options in pros and cons, being available for follow-up. Mentoring is never a one-time exercise. Not criticizing their decisions. You may disagree with their decision, but it's their decision, especially if they've considered it. Being proud of the mentee, being proud of their accomplishments, following them over the years. And when they've gotten in trouble or failed to get the job that they wanted, always be there for them, not just in the good times, but in the times that are difficult for them professionally. I think that's one of the most important things.  Even today, I mentor three or four clinical department chairmen, and people ranging from full professors to newly appointed assistant professors. Now that I'm retired, mentoring is the one activity that I've really retained. It's extraordinarily satisfying, and I'm proud of the people that I've mentored. But it's their accomplishments, and the key aspect of mentoring is never to take credit. Dave Johnson: I'll give you credit for mentoring me, and I appreciate it. You were very instrumental at a very decisive point in my career when the old Southeast Cancer Group disbanded, and we were looking for a new cooperative group home. And you were instrumental in helping my institution come into the ECOG fold, and not just as a very junior member, but really as a player. And I'll never forget that, and we'll always appreciate that very much. Pat Loehrer: Ditto on my side, too. Dave Johnson: John, you mentioned that you're retired. What do you like to do in your "free time” if you're not mentoring? Dr. John Glick: Life is good. My daughter says I have a disease, O-L-D. My grandson says, “He's not old; he's almost 80. Look how well he's done.” “Here's $20.” I'm having fun. We are fortunate to have homes in different places. We spend the summer up in the Thousand Islands on the St. Lawrence River, spring and fall down in Charleston, then lots of time in Philadelphia. We travel. I play golf poorly. I'm getting a chance to read history again, go back to one of my great loves. I'm with my children and grandchildren more. I lost my first wife. I've been remarried for about twelve years, and I'm enjoying every moment of that. I'm not bored, but I do wake up in the morning with no anxiety, no realization that I have to herd sheep or herd cats. I have no metrics, I have no RVUs,  not behind of the EMR.  Dave Johnson: You're making it sound too good, John.  Dr. John Glick: We're having fun. And I have not been bored. I've not been down in the dumps. Each day brings a different aspect. We see a lot more of our friends. I exercise. I deal with the health problems that people get when they get older, and I have plenty of those. Seeing doctors takes a lot of time, but I'm grateful that I'm having these few years of retirement. I'm one of the people who is most fortunate to have attained everything they wanted to do in their professional life, and now I'm trying to do some of the same in my personal life. Dave Johnson: John, Pat and I both love to read. We love history. You mentioned that you're reading some history. Is there a book that you've read recently that you might recommend to us? Dr. John Glick: “the Last of the Breed” {With the Old Breed} It's about a private in the Pacific campaign who was not a commissioned officer; it's just a grunt on the ground. It brings the horrors of the Pacific island campaigns to life. But there's a huge number of books, some historical fiction. I'm a great fan of Bernard Cornwell, who's written about the Medieval times, Azincourt, 1356. I'll read two or three books a week. I'm devoted to my Kindle. Dave Johnson: If you could go back in time and give your younger self a piece of advice, what would that advice be?   Dr. John Glick: Try and achieve more of a work-life balance. I didn't have any choice. If I didn't do the consult, it didn't get done. That's not the situation today. But I have a second piece of advice, don't treat medicine as a 9 to 5 job. If a patient is sick, stay with the patient. Give the patient your home or cell phone number. Remember, medicine is not just a profession, but it can be a calling. Too few of our physicians today regard medicine as a calling. And even if you're employed, as most of us are by an academic or other institution, do what's right for the patient, not just what's right for your timesheet or the EMR. Remember that the patient is at the center of all we do and that medicine is a calling for some people, as it was for me. Dave Johnson: Great advice, John. Great advice.  Well, I want to thank Dr. Glick for joining Pat and me. This has been a delight. You're one of our role models and heroes.  I want to thank all of our listeners of Oncology, Etc., which is an ASCO educational podcast where we will talk about oncology medicine and other topics. If you have an idea for a topic or a guest you'd like us to interview, please email us at education@asco.org. To stay up to date with the latest episodes and explore other educational content of ASCO, please visit education.asco.org. Thanks again. Pat, before we go, I've got an important question for you. I've been trying to school you recently, and you've failed miserably. So I'm going to ask you, why is it that McDonald's doesn't serve escargot? Pat Loehrer: I can't do it. I don't know. I give up.  Dave Johnson: It's not fast food. Pat Loehrer: I like that. It's good.  The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.   Guests on this podcast express their own opinions, experiences, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.    

After undergoing a mastectomy, women can either proceed with a reconstruction or “go flat”, but today's guest says that the correct decision is what's best for the patient. As an oncoplastic breast surgeon at City of Hope Chicago, Dr. Carolyn Bhakta performs surgical procedures for patients with breast malignancies, ranging from the earliest to advanced stages of disease. Dr. Bhakta works closely with her patients to understand their cancer needs and goals to identify the most appropriate surgical options and to heal her patients both physically and emotionally. When it comes to breast cancer surgery, there are no wrong decisions – only personal decisions. Here today to discuss the very personal choice that some women make to go flat and to help change the narrative surrounding it is Dr. Carolyn Bhakta.

Head and Neck Cancer Awareness Month with guest Dr. Ansley Roche April 30, 2023 Yale Cancer Center visit: http://www.yalecancercenter.org email: canceranswers@yale.edu call: 203-785-4095

Cost of Cancer drugs - VP's lecture

“The bell can have so much more meaning and significance than just the end of treatment. So, work with your patients to define what the significance of that bell can mean,” ONS member Monica Cfarku, RN, MSN, BMTCN®, CCM, NE-BC, associate vice president and chief of oncology nursing at Duke Cancer Institute in Durham, NC, and member of the North Carolina Triangle ONS Chapter, told Jaime Weimer, MSN, RN, AGCNS-BC, AOCNS®, oncology clinical specialist at ONS. Cfarku discussed the ethics of the bell that patients with cancer ring following the completion of their treatment and how her institution has redefined the bell's ritual. You can earn free NCPD contact hours by completing the evaluation we've linked in the episode notes. Music Credit: “Fireflies and Stardust” by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at myoutcomes.ons.org by April 28, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: The learner will report an increase in knowledge related to treatment bell meaning and options. Episode Notes Complete this evaluation for free NCPD. Oncology Nursing Podcast Episode 78: Ethical Distress Impacts Nursing Practice ONS Voice articles: Four R's and Resilience Approach Help Oncology Nurses Respond to Morally Distressing Challenges Redefining the Bell Makes the Ritual Inclusive for All Patients With Cancer Use the Evidence to Integrate Ethics in Teleoncology Care How to Have Ethical Discussions in Your Practice ONS Moral Resilience Huddle Card™ MD Anderson Cancer Center: Ringing the Bell Marks a Milestone in Cancer Treatment Duke Cancer Institute To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From Today's Episode “The bell has typically been associated with completion of treatment, and the patient is now considered free of cancer. The challenge with that is when patients that will never get to experience that—because there are certain cancers now that are essentially chronic conditions—they hear that bell and that is not a good sound for them. That can bring a lot of emotions around how they're never going to get to that point.” Timestamp (TS) 02:19 “As nurses, it is our duty to recognize an ethical situation and help to determine what that next action or decision is in those situations. We really need to be applying our ethical sensitivity.” TS 04:06 “The bell doesn't just have to be for the end of treatment. It can be the end of a particular journey, or ringing the bell for courage before you walk in. It can be used for anything.” TS 13:14 “I've seen patients ring the bell before walking into the building. . . . I've been asked to meet patients at the bell on their last day of treatment so they can ring it in celebration. . . . I've seen non-oncology patients that are going into a different part of the campus and their family ring it, and I love to see that, as our bell is being used to inspire hope and courage to so many other patients across Duke University. . . . I've seen staff ring it. . . . This little project has really had a reverberating effect that we did not even anticipate.” TS 16:23 “The bell can have so much more meaning and significance than just the end of treatment. So, work with your patients to define what the significance of that bell can mean.” TS 20:45

Go online to PeerView.com/GFT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Oncology nurse professionals play a particularly important role in providing high-quality and increasingly personalized care to patients with acute myeloid leukemia (AML)—but how current are you with the “real-world” practice of nursing care in AML? Find out in this activity, featuring an oncology nurse's expert overview of nursing principles that can be used to modernize care and optimize the use of innovative targeted therapies (such as FLT3, IDH1/2, and BCL-2 inhibitors) across the treatment continuum. Upon completion of this activity, participants should be better able to: Recognize clinical symptoms, patient-related factors, and molecular/genetic features that influence AML treatment decisions and prognosis; Summarize efficacy and safety evidence related to novel targeted and epigenetic options for the management of newly diagnosed AML, postremission disease, and the relapsed/refractory setting; Educate patients with AML about therapeutic choices with novel agent classes, treatment expectations, dosing and adherence, and safety considerations; and Manage adverse events experienced by patients with AML receiving novel targeted and epigenetic options as part of their care.

This episode features Stephen Gruber, Vice President at City of Hope National Medical Center and Director of City of Hope's Center for Precision Medicine, Stacy Gray, Chief of City of Hope's Division of Clinical Cancer Genomics and Deputy Director of its Center for Precision Medicine, Sumanta “Monty” Pal, Co-Director of the Kidney Cancer Program at City of Hope, and Rick Baehner, M.D., Chief Medical Officer at Exact Sciences Precision Oncology. Here, they discuss their experience building their precision oncology program at City of Hope and how it has improved patient care and clinical outcomes across the organization.This episode is sponsored by Exact Sciences

Dr Bill Nelson speaks with Donna Berizzi, the Senior Director of Oncology Nursing at Johns Hopkins, about the past, present and future of oncology nursing.

This week we sit down with Alison Gulbis, PharmD, BCOP, Kamakshi Rao, PharmD, BCOP, FASHP, and Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA to discuss their work on the Oncology Workforce Collaborative. Alison is a Clinical Pharmacy Manager at the University of Texas MD Anderson Cancer Center in Houston, TX. She obtained her PharmD at the University of Florida and completed her PGY1 and PGY2 residencies at the Medical University of South Carolina. She has been in clinical practice for 19 years at MD Anderson and manages a team of clinical pharmacy specialists in pediatric hematology/oncology and adult stem cell transplant.Kamakshi is an Interim Director of Pharmacy at the University of North Carolina Medical Center in Chapel Hill. She oversees Adult Ambulatory and Acute Clinical Services as well as the hospital's academic enterprises, including resident and student training programs.  Additionally, she leads the department's growing efforts around diversity, equity, and inclusion. She spent 20 years in direct patient care, working with patients undergoing bone marrow transplants at the North Carolina Cancer Hospital before moving into her current role.Zahra is a Clinical Pharmacy Manager in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Health System (TUKHS). She earned her PharmD and MBA from the UMKC School of Pharmacy and the Henry W. Bloch School of Management. She completed residency training at The Ohio State University Medical Center and The Huntsman Cancer Institute at the University of Utah. She has been a board-certified oncology pharmacist since 2012. In 2022, she was the recipient of the ASTCT Pharmacy Special Interest Group Lifetime Achievement Award and ASCO's 40 Under 40 in Cancer award.You can read more here: https://accpjournals.onlinelibrary.wiley.com/doi/10.1002/jac5.1693